Podcasts

Few drugs in oncology have transformed the way we take care of patients. Ibrutinib is one such drug, and it belongs to a class called “BTK inhibitors.” In this episode, Chadi captures the story of developing the drug through the eyes of Dr. Jeff Sharman, a prolific investigator and researcher; he is the director of research at the Willamette Valley Cancer Institute as well as the medical director of hematology research for The US Oncology Network.

Jennifer Fried, MBA, most recently the CEO of ExplORer Surgical, joins the show to share her story as a co-founder of a successful startup health technology company.

What do we know about various diets and their association with cancer? Have you ever wondered what the evidence shows? To answer this important question, Chadi hosts two specialists from Memorial Sloan Kettering Cancer Center: Urvi Shah, MD, hematologist oncologist (myeloma expert and a cancer survivor herself), and Neil Lyengar, MD, medical oncologist (breast cancer expert).

Scott Eggener, MD, University of Chicago, and Jonathan Epstein, MD, The Johns Hopkins Medical Institutions, join the show to debate whether Gleason Score 6 prostate cancer should be renamed to non-cancer.

Chadi is delighted and honored to host an icon and pioneer in precision medicine and the molecular understanding of cancer as we know it: Ray Kurzrock, MD, FACP, Center Associate Director and Professor at the Medical College of Wisconsin as well as CMO of the WIN consortium

To educate on oncology in the Arab world—home to over 400 million people—Chadi welcomes a new and renowned guest: Humaid AlShamsi, MD, President of the Emirates Oncology Society and Adjunct Clinical Professor of Oncology at the University of Sharjah (UAE).

To shed light on the differences in oncologic care between the US and the EU, Chadi invites a returning guest as well as a newcomer: Jarushka Naidoo, MBBCH, MD, Chair of the Thoracic Oncology Division, Beaumont RCSI Cancer Centre (Dublin, Ireland), and Marina Chiara Garassino, MD, Professor of Medicine, University of Chicago Medicine.

In his second appearance on the show, Christopher Booth, MD, Professor in the Departments of Oncology and Medicine as well as a Health Services Researcher, Queen’s University (Canada), shares his unique career path and early considerations of conflicts of interest in the medical world, how the influences of pharma relationships are more subtle than expected, whether you can be a clinical trialist without working with pharma, and how the system can be changed to truly benefit patients.